The shadow of generic challenges has long loomed above copyright’s famous drug, Viagra, raising questions about the outlook of similar medicinal stakes. While initial years saw significant gains, the intellectual property end has allowed the way for cheaper alternatives, potentially diminishing earnings and posing a genuine risk for shareholders